Filtered By:
Specialty: Pharmaceuticals
Condition: Heart Failure

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 25 results found since Jan 2013.

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Patterns Changing for Heart Disorder Hospitalizations in Canada
FRIDAY, July 10, 2020 -- Standardized hospitalization rates declined for coronary artery and vascular disease, heart rhythm disorders, stroke, and heart failure in Canada from 2007 through 2016, according to a study published online July 1 in the...
Source: Drugs.com - Pharma News - July 10, 2020 Category: Pharmaceuticals Source Type: news

Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation
IRVINE, CA – May 8, 2020 – Johnson & Johnson Medical Devices Companies* today announced that Biosense Webster, Inc.’s THERMOCOOL SMARTTOUCH® SF Ablation Catheter, evaluated in the PRECEPT study for the treatment of persistent atrial fibrillation (AF), resulted in freedom from any documented, symptomatic atrial arrhythmias at 15 months post-procedure for eight out of ten study participants (80.4 percent).1 Use of the THERMOCOOL SMARTTOUCH SF CATHETER for persistent atrial fibrillation is investigational only. This PRECEPT study data support a Premarket Approval supplement application to the U.S. Food and Drug Adm...
Source: Johnson and Johnson - May 12, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

FDA clears Berkeley health tech startup's algorithms to detect heart problems
Berkeley health-tech startup Eko was granted FDA clearance today to take its algorithm for detecting atrial fibrillation to the market.   The algorithm, in tandem with a digital stethoscope, is meant to be used to screen for atrial fibrillation and other types of heart disease caused by heart murmurs — a condition that can result in a stroke or heart failure if left untreated. Connor Landgraf, CEO and co-founder of Eko, said it is the first in-office screening algorithm used with a stethoscope…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 28, 2020 Category: Pharmaceuticals Authors: Brian Rinker Source Type: news

Skin-cells-turned-to-heart-cells help unravel genetic underpinnings of cardiac function
Genome-wide association studies have uncovered more than 500 genetic variants linked to heart function, everything from heart rate to irregular rhythms that can lead to stroke, heart failure or other complications. But since most of these variations fall into areas of the genome that don't encode proteins, exactly how they influence heart function has remained unclear.
Source: World Pharma News - September 30, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Why you might think twice about wine with dinner
Having a single glass of wine with dinner every night could cut your life expectancy by about two years, according to an international study linking increased alcohol consumption with a higher risk of developing fatal diseases.   The research, published in the medical journal The Lancet, found that people who drank the equivalent of about six glasses of wine a week or more increased their risk of stroke, heart disease, heart failure, fatal hypertensive disease and fatal aortic aneurysm. The researchers…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 13, 2018 Category: Pharmaceuticals Authors: Anne Stych Source Type: news

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors
AstraZeneca has announced results from a new analysis of its landmark CVD-REAL study, the first large real-world evidence study of its kind evaluating the risk of all-cause death (ACD), hospitalisation for heart failure (hHF), heart attack (myocardial infarction or MI) and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines.
Source: World Pharma News - March 14, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news